A detailed pathologic analysis was performed on Smn(-/-);SMN2 mice as a mouse model for human type I spinal muscular atrophy (SMA). We provide new data concerning changes in the spinal cord, neuromuscular junctions and muscle cells, and in the organs of the immune system. The expression of 10 synaptic proteins was analyzed in 3-dimensionally reconstructed neuromuscular junctions by confocal microscopy. In addition to defects in postsynaptic occupancy, there was a marked reduction in calcitonin gene-related peptide and Rab3A in the presynaptic motor terminals of some, but not all, of the skeletal muscles analyzed. Defects in the organization of presynaptic nerve terminals were also detected by electron microscopy. Moreover, degenerative changes in muscle cells, defective postnatal muscle growth, and prominent muscle satellite cell apoptosis were also observed. All of these changes occurred in the absence of massive loss of spinal cord motoneurons. On the other hand, astroglia, but not microglia, increased in the ventral horn of newborn SMA mice. In skeletal muscles, the density of interstitial macrophages was significantly reduced, and monocyte chemotactic protein-1 was downregulated. These findings raise questions regarding the primary contribution of a muscle cell defect to the SMA phenotype.

Download full-text PDF

Source
http://dx.doi.org/10.1097/NEN.0b013e31821cbd8bDOI Listing

Publication Analysis

Top Keywords

spinal muscular
8
muscular atrophy
8
spinal cord
8
neuromuscular junctions
8
muscle cells
8
skeletal muscles
8
muscle
5
defective neuromuscular
4
neuromuscular junction
4
junction organization
4

Similar Publications

Background: Due to improved treatment options, more SMA patients reach childbearing age. Currently, limited data on pregnant SMA patients is available, especially in relation to disease-modifying therapies (DMT). This case report helps to elucidate new approaches for future guidelines in the management of pregnancy and SMA.

View Article and Find Full Text PDF

Background: Vanishing white matter disease (VWMD) is a rare autosomal recessive leukoencephalopathy. It is typified by a gradual loss of white matter in the brain and spinal cord, which results in impairments in vision and hearing, cerebellar ataxia, muscular weakness, stiffness, seizures, and dysarthria cogitative decline. Many reports involve minors.

View Article and Find Full Text PDF

Cerebral venous sinus thrombosis is an uncommon sequela of low intracranial pressure, which may result from a lumbar puncture (LP). We describe a case of a patient in their 40s presenting with 48 hours of persistent headache following intrathecal administration of nusinersen for spinal muscular atrophy (SMA) type 3. There were no focal neurological signs or symptoms apart from baseline symmetrical proximal limb weakness attributed to SMA.

View Article and Find Full Text PDF

Catecholaminergic dysfunction drives postural and locomotor deficits in a mouse model of spinal muscular atrophy.

Cell Rep

January 2025

Center for Motor Neuron Biology and Disease, Columbia University, New York, NY 10032, USA; Department of Neurology, Columbia University, New York, NY 10032, USA; Department of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA. Electronic address:

Article Synopsis
  • Understanding posture is crucial for how mammals move, and dysregulation of certain brain chemicals, specifically dopamine and noradrenaline, can lead to motor problems in diseases like spinal muscular atrophy (SMA).
  • Research using a mouse model of SMA revealed that the loss of synapses in the spinal neurons, caused by non-cell autonomous mechanisms, contributes to motor dysfunction and postural issues.
  • Restoring a specific protein (survival motor neuron) in either catecholaminergic or serotonergic neurons can improve movement, but significant postural issues only improve with restoration in both neuron types or treatment with l-dopa, highlighting new potential treatment strategies.
View Article and Find Full Text PDF

Background: Nusinersen and risdiplam are U.S. Food and Drug Administration (FDA)-approved treatments for spinal muscular atrophy (SMA).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!